Quanterix (QTRX) Stock Price, News & Analysis

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTRX shares.
View QTRX analyst ratings or view top-rated stocks.

6 analysts have issued 12-month target prices for Quanterix's shares. Their QTRX share price targets range from $30.00 to $34.00. On average, they expect the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 104.2% from the stock's current price.
View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts.

Quanterix's stock was trading at $27.34 on January 1st, 2024. Since then, QTRX stock has decreased by 42.7% and is now trading at $15.67.
View the best growth stocks for 2024 here.

Quanterix saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,000,000 shares, a drop of 18.7% from the March 15th total of 1,230,000 shares. Based on an average daily trading volume, of 334,600 shares, the short-interest ratio is presently 3.0 days. Currently, 2.9% of the shares of the company are short sold.
View Quanterix's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our QTRX earnings forecast.

Quanterix Co. (NASDAQ:QTRX) announced its earnings results on Thursday, February, 29th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.05. The business earned $31.55 million during the quarter, compared to the consensus estimate of $27.92 million. Quanterix had a negative trailing twelve-month return on equity of 9.15% and a negative net margin of 26.42%.

Quanterix updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $139.0 million-$144.0 million, compared to the consensus revenue estimate of $138.2 million.

15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).

Quanterix (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix's stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.05%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Laurie J Olson, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Masoud Toloue, Michael A Doyle and William P Donnelly.
View institutional ownership trends.

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.